Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing sales forecast for tardive dyskinesia (TD) drug Ingrezza commanded much of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback